EG132A

EG132A is an investigational gene therapy product under development by EG 427 for the treatment of an undisclosed neuromuscular disease, as well as for potential use in undisclosed sensory and neurodegenerative diseases. The specific mechanism of action, molecular target, and detailed composition have not been publicly disclosed. However, based on the company's pipeline focus and related assets (such as EG110A), it is likely that EG132A utilizes a non-replicative herpes simplex virus type 1 (HSV-1) vector platform to deliver genetic material selectively to targeted neuronal populations[1][4]. This approach aims to provide long-lasting therapeutic effects by modulating or correcting underlying pathophysiology at the level of affected neurons.